Journal of Gastric Cancer

The Korean Gastric Cancer Association (대한위암학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy of Different Number of XELOX or SOX Chemotherapy Cycles After D2 Resection for Stage III Gastric Cancer

  • Yu, Yuanyuan (Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital) ;
  • Zhang, Zicheng (School of Biomedical Engineering, Wenzhou Medical University) ;
  • Meng, Qianhao (Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital) ;
  • Wang, Ke (Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital) ;
  • Li, Qingwei (Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital) ;
  • Ma, Yue (Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital) ;
  • Yao, Yuanfei (Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital) ;
  • Sun, Jie (School of Biomedical Engineering, Wenzhou Medical University) ;
  • Wang, Guangyu (Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital)
  • Received : 2021.12.12
  • Accepted : 2022.03.17
  • Published : 2022.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: We aimed to explore whether the prognosis of patients treated with capecitabine and oxaliplatin (XELOX) or S-1 and oxaliplatin (SOX) regimens who received fewer cycles of chemotherapy after D2 radical resection for gastric cancer (GC) would be non-inferior to that of patients who received the standard number of cycles of chemotherapy. Materials and Methods: Data on patients who received XELOX or SOX chemotherapy after undergoing D2 radical resection at Harbin Medical University Cancer Hospital between January 2011 and May 2016 were collected. Results: In patients who received 4, 6, and 8 cycles of chemotherapy, the 5-year overall survival (OS) rates were 59.4%, 64.8%, and 62.7%, respectively. Compared to patients who received 4 cycles of chemotherapy, those who received 6 cycles (hazard ratio [HR], 0.882; 95% confidence interval [CI], 0.599-1.299; P=0.52) or 8 cycles (HR, 0.882; 95% CI, 0.533-1.458; P=0.62) of chemotherapy did not exhibit significantly prolonged OS. The 3-year disease-free survival (DFS) rate of patients who received 4, 6, and 8 cycles of chemotherapy was 62.1%, 67.2%, and 60.8%, respectively. Compared to patients who received 4 cycles of chemotherapy, those who received 6 cycles (HR, 0.835; 95% CI, 0.572-1.221; P=0.35) or 8 cycles (HR, 0.972; 95% CI, 0.606-1.558; P=0.91) of chemotherapy did not show significantly prolonged DFS. However, the 3-year DFS and 5-year OS rates of patients who received 6 cycles of chemotherapy appeared to be superior to those of patients who received 4 and 8 cycles of chemotherapy. Conclusions: For patients with stage III GC, 4 to 6 cycles of XELOX or SOX chemotherapy may be a favorable option. This study provides a rationale for further randomized clinical trials.

Keywords

Acknowledgement

We thank Spandidos Publications for English language editing.

References

  1. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020;396:1204-1222. https://doi.org/10.1016/S0140-6736(20)30925-9
  2. Yusefi AR, Bagheri Lankarani K, Bastani P, Radinmanesh M, Kavosi Z. Risk factors for gastric cancer: a systematic review. Asian Pac J Cancer Prev 2018;19:591-603.
  3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-249. https://doi.org/10.3322/caac.21660
  4. Kendler KS, Thornton LM, Pedersen NL. Tobacco consumption in Swedish twins reared apart and reared together. Arch Gen Psychiatry 2000;57:886-892. https://doi.org/10.1001/archpsyc.57.9.886
  5. Li WY, Han Y, Xu HM, Wang ZN, Xu YY, Song YX, et al. Smoking status and subsequent gastric cancer risk in men compared with women: a meta-analysis of prospective observational studies. BMC Cancer 2019;19:377. https://doi.org/10.1186/s12885-019-5601-9
  6. Camargo MC, Goto Y, Zabaleta J, Morgan DR, Correa P, Rabkin CS. Sex hormones, hormonal interventions, and gastric cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2012;21:20-38.
  7. Lou L, Wang L, Zhang Y, Chen G, Lin L, Jin X, et al. Sex difference in incidence of gastric cancer: an international comparative study based on the Global Burden of Disease Study 2017. BMJ Open 2020;10:e033323. https://doi.org/10.1136/bmjopen-2019-033323
  8. Gao JP, Xu W, Liu WT, Yan M, Zhu ZG. Tumor heterogeneity of gastric cancer: From the perspective of tumor-initiating cell. World J Gastroenterol 2018;24:2567-2581. https://doi.org/10.3748/wjg.v24.i24.2567
  9. Ke B, Liang H. Current status of lymph node dissection in gastric cancer. Chin J Cancer Res 2021;33:193-202. https://doi.org/10.21147/j.issn.1000-9604.2021.02.07
  10. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010;11:439-449. https://doi.org/10.1016/S1470-2045(10)70070-X
  11. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. J Clin Oncol 2004;22:2767-2773. https://doi.org/10.1200/JCO.2004.10.184
  12. Xu J, Shen L, Shui Y, Yu W, Guo Q, Yu R, et al. Patterns of recurrence after curative D2 resection for gastric cancer: Implications for postoperative radiotherapy. Cancer Med 2020;9:4724-4735. https://doi.org/10.1002/cam4.3085
  13. Zeng WJ, Hu WQ, Wang LW, Yan SG, Li JD, Zhao HL, et al. Long term follow up and retrospective study on 533 gastric cancer cases. BMC Surg 2014;14:29. https://doi.org/10.1186/1471-2482-14-29
  14. Matsuda T, Saika K. The 5-year relative survival rate of stomach cancer in the USA, Europe and Japan. Jpn J Clin Oncol 2013;43:1157-1158. https://doi.org/10.1093/jjco/hyt166
  15. D'Angelica M, Gonen M, Brennan MF, Turnbull AD, Bains M, Karpeh MS. Patterns of initial recurrence in completely resected gastric adenocarcinoma. Ann Surg 2004;240:808-816. https://doi.org/10.1097/01.sla.0000143245.28656.15
  16. Chang SC, Liu KH, Hung CY, Tsai CY, Hsu JT, Yeh TS, et al. Adjuvant chemotherapy improves survival in stage III gastric cancer after D2 surgery. J Cancer 2018;9:81-91. https://doi.org/10.7150/jca.21989
  17. Diaz-Nieto R, Orti-Rodriguez R, Winslet M. Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. Cochrane Database Syst Rev 2013;CD008415.
  18. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) GroupPaoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010;303:1729-1737. https://doi.org/10.1001/jama.2010.534
  19. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet 2012;379:315-321. https://doi.org/10.1016/S0140-6736(11)61873-4
  20. Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:1389-1396. https://doi.org/10.1016/S1470-2045(14)70473-5
  21. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007;357:1810-1820. https://doi.org/10.1056/NEJMoa072252
  22. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 2011;29:4387-4393. https://doi.org/10.1200/JCO.2011.36.5908
  23. Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial. J Clin Oncol 2019;37:1296-1304. https://doi.org/10.1200/JCO.18.01138
  24. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730. https://doi.org/10.1056/NEJMoa010187
  25. Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol 2012;30:268-273.
  26. Park SH, Sohn TS, Lee J, Lim DH, Hong ME, Kim KM, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol 2015;33:3130-3136. https://doi.org/10.1200/JCO.2014.58.3930
  27. Park SH, Lim DH, Sohn TS, Lee J, Zang DY, Kim ST, et al. A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. Ann Oncol 2021;32:368-374. https://doi.org/10.1016/j.annonc.2020.11.017
  28. Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol 2018;19:616-628. https://doi.org/10.1016/S1470-2045(18)30132-3
  29. Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, et al. Adjuvant chemoradiotherapy with epirubicin, cisplatin, and fluorouracil compared with adjuvant chemoradiotherapy with fluorouracil and leucovorin after curative resection of gastric cancer: results from CALGB 80101 (Alliance). J Clin Oncol 2017;35:3671-3677. https://doi.org/10.1200/JCO.2017.74.2130
  30. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20. https://doi.org/10.1056/NEJMoa055531
  31. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393:1948-1957. https://doi.org/10.1016/S0140-6736(18)32557-1
  32. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715-1721. https://doi.org/10.1200/JCO.2010.33.0597
  33. Kang YK, Yook JH, Park YK, Lee JS, Kim YW, Kim JY, et al. PRODIGY: a phase III study of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer. J Clin Oncol 2021;39:2903-2913. https://doi.org/10.1200/JCO.20.02914
  34. Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol 2021;22:1081-1092. https://doi.org/10.1016/S1470-2045(21)00297-7
  35. Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, et al. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun (Lond) 2021;41:747-795. https://doi.org/10.1002/cac2.12193
  36. Wang XX, Li S, Xie TY, Lu YX, Guo X, Lin C. Early results of the randomized, multicenter, controlled evaluation of S-1 and oxaliplatin as neoadjuvant chemotherapy for Chinese advanced gastric cancer patients (RESONANCE Trial). J Clin Oncol 2020;38:280.
  37. Hofheinz RD, Hegewisch-Becker S, Kunzmann V, Thuss-Patience P, Fuchs M, Homann N, et al. Trastuzumab in combination with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group. Int J Cancer 2021;149:1322-1331. https://doi.org/10.1002/ijc.33696
  38. Rivera F, Izquierdo-Manuel M, Garcia-Alfonso P, Martinez de Castro E, Gallego J, Limon ML, et al. Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. Eur J Cancer 2021;145:158-167. https://doi.org/10.1016/j.ejca.2020.12.005
  39. Hofheinz RD, Haag JM, Ettrich TJ, Borchert K, Kretzschmar A, Teschendorf C, et al. Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: final results of the PETRARCA multicenter randomized phase II trial of the AIO. J Clin Oncol 2020;38:4502. https://doi.org/10.1200/jco.2020.38.15_suppl.4502
  40. Tang ZQ, Wang Y, Liu D, Yu YY, Cui YH, Tang C, et al. Phase II study of neoadjuvant camrelizumab combined with chemoradiation for locally advanced proximal gastric cancer. Ann Oncol 2021;32:S1040-S1075.
  41. Lauren P. The two histological main types of gastric carcinoma: diffuse and so called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31-49. https://doi.org/10.1111/apm.1965.64.1.31
  42. Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol 2017;3:1197-1203. https://doi.org/10.1001/jamaoncol.2016.6762
  43. Choi YY, Kim H, Shin SJ, Kim HY, Lee J, Yang HK, et al. Microsatellite instability and programmed cell death-ligand 1 expression in stage II/III gastric cancer: post hoc analysis of the CLASSIC randomized controlled study. Ann Surg 2019;270:309-316. https://doi.org/10.1097/SLA.0000000000002803
  44. Pietrantonio F, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol 2019;37:3392-3400. https://doi.org/10.1200/jco.19.01124
  45. Cai Z, Rui W, Li S, Fingerhut A, Sun J, Ma J, et al. Microsatellite status affects tumor response and survival in patients undergoing neoadjuvant chemotherapy for clinical stage III gastric cancer. Front Oncol 2020;10:614785. https://doi.org/10.3389/fonc.2020.614785
  46. Kim JW, Cho SY, Chae J, Kim JW, Kim TY, Lee KW, et al. Adjuvant chemotherapy in microsatellite instability-high gastric cancer. Cancer Res Treat 2020;52:1178-1187.
  47. Haag GM, Czink E, Ahadova A, Schmidt T, Sisic L, Blank S, et al. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy. Int J Cancer 2019;144:1697-1703. https://doi.org/10.1002/ijc.32030
  48. Nakamura Y, Yamanaka T, Chin K, Cho H, Katai H, Terashima M, et al. Survival outcomes of two phase 2 studies of adjuvant chemotherapy with S-1 plus oxaliplatin or capecitabine plus oxaliplatin for patients with gastric cancer after D2 gastrectomy. Ann Surg Oncol 2019;26:465-472. https://doi.org/10.1245/s10434-018-7063-8
  49. Jiang Z, Sun Y, Zhang W, Cui C, Yang L, Zhou A. Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: a single-center retrospective study. Asia Pac J Clin Oncol 2020;16:180-186. https://doi.org/10.1111/ajco.13321
  50. Grothey A, Sobrero AF, Shields AF, Yoshino T, Paul J, Taieb J, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med 2018;378:1177-1188. https://doi.org/10.1056/NEJMoa1713709
  51. Andre T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T, Souglakos I, et al. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol 2020;21:1620-1629. https://doi.org/10.1016/s1470-2045(20)30527-1
  52. Yoshikawa T, Terashima M, Mizusawa J, Nunobe S, Nishida Y, Yamada T, et al. Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104 [OPAS-1]): an open-label, phase 3, non-inferiority, randomised trial. Lancet Gastroenterol Hepatol 2019;4:208-216. https://doi.org/10.1016/S2468-1253(18)30383-2
  53. Feng WM, Tang CW, Guo HH, Bao Y, Fei MY. Prolonged adjuvant capecitabine chemotherapy improved survival of stage IIIA gastric cancer after D2 gastrectomy. Biomed Pharmacother 2015;72:140-143. https://doi.org/10.1016/j.biopha.2015.03.003
  54. Liu Z, Wang Y, Shan F, Ying X, Zhang Y, Li S, et al. 5-FU-based doublet regimen in patients receiving perioperative or postoperative chemotherapy for locally advanced gastric cancer: when to start and how long should the regimen last? Cancer Manag Res 2021;13:147-161. https://doi.org/10.2147/CMAR.S285361
  55. Qu JL, Li X, Qu XJ, Zhu ZT, Zhou LZ, Teng YE, et al. Optimal duration of fluorouracil-based adjuvant chemotherapy for patients with resectable gastric cancer. PLoS One 2013;8:e83196. https://doi.org/10.1371/journal.pone.0083196
  56. Chen L, Zhang C, Yao Z, Cui M, Xing J, Yang H, et al. Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study. BMC Cancer 2021;21:974. https://doi.org/10.1186/s12885-021-08717-4